Immutep Limited
NASDAQ:IMMPBiotechnology
Healthcare
$0.37 +0.64%
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
52W Low $0.29High $3.53
Volume 3.10M
Average 13.46M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$62.05M
FY 2025 · Annual
Investing Cash Flow
-$38.53M
FY 2025 · Annual
Financing Cash Flow
-$525,121.00
FY 2025 · Annual
Cash Flow Statement
AUD
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Depreciation & Amortization | 2.07M | 2.06M | 2.06M | 2.26M | 2.39M |
| Deferred Income Tax | (7.29M) | 0 | (4.99M) | 0 | 0 |
| Stock-Based Compensation | 1.7M | 1.49M | 2M | 1.8M | 1.16M |
| Change in Working Capital | (1.99M) | (1.56M) | 764.6K | 3.46M | (8.54M) |
| Accounts Receivables | (2.83M) | (2.25M) | (1.61M) | 601.77K | (2.52M) |
| Inventory | 0 | 813.92K | 0 | 0 | 0 |
| Accounts Payables | 1.38M | 1.44M | 3.27M | 0 | 0 |
| Other Working Capital | (543.42K) | (1.56M) | (900.11K) | 2.86M | (6.02M) |
| Other Non-Cash Items | 17.77M | (8.04K) | 4.17M | 379.87K | 4.37M |
| Operating Cash Flow | (17.64M) | (30.23M) | (35.88M) | (34.82M) | (62.05M) |
| Capital Expenditures | (15.6K) | (22.91K) | (47K) | (932.37K) | (45.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (20.09M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 16K | (903.15K) | (38.49M) |
| Investing Cash Flow | (15.6K) | (22.91K) | (31K) | (21.02M) | (38.53M) |
| Debt Repayment | (214.38K) | (222.54K) | (211.97K) | (226.49K) | (270.67K) |
| Common Stock Issued | 43.31M | 52.98M | 80.08M | 100.24M | (164.79K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.59M | (2.43M) | (3.83M) | (4.83M) | (254.46K) |
| Financing Cash Flow | 52.68M | 50.33M | 76.04M | 95.18M | (525.12K) |
| Effect of Forex Changes | (752.84K) | (671.04K) | 3.3M | (967.73K) | 6.73M |
| Net Change in Cash | 34.27M | 19.4M | 43.42M | 38.37M | (94.38M) |
| Free Cash Flow | (17.66M) | (30.25M) | (35.93M) | (35.75M) | (62.1M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$61.4M
+ D&A$2.4M
+ Stock-Based Comp$1.2M
+ Deferred Tax$0
- Working Capital-$8.5M
+ Other Non-Cash$4.4M
= Operating Cash Flow-$62.0M
- Capex-$45.8K
= Free Cash Flow-$62.1M
Analysis
FY2025 free cash flow is -$62.1M. FCF conversion is 101.1% of net income. Operating cash flow was -$62.0M, with capex of -$45.8K. The largest bridge item is Working Capital at -$8.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Sep 11, 2026 | |
| 6-K | 6-K filing | Sep 2, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 6-K | 6-K filing | Jul 14, 2026 | |
| 6-K | 6-K filing | Jun 5, 2026 |
Does IMMP generate free cash flow?
Immutep Limited (IMMP) generated -$62.10M of free cash flow in fiscal 2025.
How much operating cash flow does IMMP produce?
Operating cash flow was -$62.05M, before capital expenditures of $45,769.00.
Continue the stock analysis
Jump to another research area for this company.